These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
493 related articles for article (PubMed ID: 17420319)
1. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Ribaï P; Pousset F; Tanguy ML; Rivaud-Pechoux S; Le Ber I; Gasparini F; Charles P; Béraud AS; Schmitt M; Koenig M; Mallet A; Brice A; Dürr A Arch Neurol; 2007 Apr; 64(4):558-64. PubMed ID: 17420319 [TBL] [Abstract][Full Text] [Related]
2. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Hart PE; Lodi R; Rajagopalan B; Bradley JL; Crilley JG; Turner C; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM Arch Neurol; 2005 Apr; 62(4):621-6. PubMed ID: 15824263 [TBL] [Abstract][Full Text] [Related]
3. Exonic deletions of FXN and early-onset Friedreich ataxia. Anheim M; Mariani LL; Calvas P; Cheuret E; Zagnoli F; Odent S; Seguela C; Marelli C; Fritsch M; Delaunoy JP; Brice A; Dürr A; Koenig M Arch Neurol; 2012 Jul; 69(7):912-6. PubMed ID: 22409940 [TBL] [Abstract][Full Text] [Related]
4. A 22-Year Follow-up Study of Long-term Cardiac Outcome and Predictors of Survival in Friedreich Ataxia. Pousset F; Legrand L; Monin ML; Ewenczyk C; Charles P; Komajda M; Brice A; Pandolfo M; Isnard R; Tezenas du Montcel S; Durr A JAMA Neurol; 2015 Nov; 72(11):1334-41. PubMed ID: 26414159 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological treatments for Friedreich ataxia. Kearney M; Orrell RW; Fahey M; Brassington R; Pandolfo M Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD007791. PubMed ID: 27572719 [TBL] [Abstract][Full Text] [Related]
6. Neurophysiological evaluation in children with Friedreich's ataxia. Sival DA; du Marchie Sarvaas GJ; Brouwer OF; Uges DR; Verschuuren-Bemelmans CC; Maurits NM; Brunt ER; van der Hoeven JH Early Hum Dev; 2009 Oct; 85(10):647-51. PubMed ID: 19775837 [TBL] [Abstract][Full Text] [Related]
7. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Di Prospero NA; Baker A; Jeffries N; Fischbeck KH Lancet Neurol; 2007 Oct; 6(10):878-86. PubMed ID: 17826341 [TBL] [Abstract][Full Text] [Related]
8. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Pineda M; Arpa J; Montero R; Aracil A; Domínguez F; Galván M; Mas A; Martorell L; Sierra C; Brandi N; García-Arumí E; Rissech M; Velasco D; Costa JA; Artuch R Eur J Paediatr Neurol; 2008 Nov; 12(6):470-5. PubMed ID: 18234531 [TBL] [Abstract][Full Text] [Related]
9. Intermediate-dose idebenone and quality of life in Friedreich ataxia. Brandsema JF; Stephens D; Hartley J; Yoon G Pediatr Neurol; 2010 May; 42(5):338-42. PubMed ID: 20399388 [TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid concentrations of idebenone in Friedreich ataxia patients. Artuch R; Aracil A; Mas A; Monrós E; Vilaseca MA; Pineda M Neuropediatrics; 2004 Apr; 35(2):95-8. PubMed ID: 15127307 [TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Di Prospero NA; Sumner CJ; Penzak SR; Ravina B; Fischbeck KH; Taylor JP Arch Neurol; 2007 Jun; 64(6):803-8. PubMed ID: 17562928 [TBL] [Abstract][Full Text] [Related]
12. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Seznec H; Simon D; Monassier L; Criqui-Filipe P; Gansmuller A; Rustin P; Koenig M; Puccio H Hum Mol Genet; 2004 May; 13(10):1017-24. PubMed ID: 15028670 [TBL] [Abstract][Full Text] [Related]
14. Progression of ataxia in patients with Machado-Joseph disease. França MC; D'Abreu A; Nucci A; Cendes F; Lopes-Cendes I Mov Disord; 2009 Jul; 24(9):1387-90. PubMed ID: 19441132 [TBL] [Abstract][Full Text] [Related]
15. International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia? Cano SJ; Hobart JC; Hart PE; Korlipara LV; Schapira AH; Cooper JM Mov Disord; 2005 Dec; 20(12):1585-91. PubMed ID: 16114019 [TBL] [Abstract][Full Text] [Related]
16. Friedreich's ataxia: idebenone treatment in early stage patients. Artuch R; Aracil A; Mas A; Colomé C; Rissech M; Monrós E; Pineda M Neuropediatrics; 2002 Aug; 33(4):190-3. PubMed ID: 12368988 [TBL] [Abstract][Full Text] [Related]
17. Characterizing gait, locomotor status, and disease severity in children and adolescents with Friedreich ataxia. Croarkin E; Maring J; Pfalzer L; Harris-Love M; Siegel K; DiProspero N J Neurol Phys Ther; 2009 Sep; 33(3):144-9. PubMed ID: 19809393 [TBL] [Abstract][Full Text] [Related]
18. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Lynch DR; Perlman SL; Meier T Arch Neurol; 2010 Aug; 67(8):941-7. PubMed ID: 20697044 [TBL] [Abstract][Full Text] [Related]
19. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Lodi R; Hart PE; Rajagopalan B; Taylor DJ; Crilley JG; Bradley JL; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM Ann Neurol; 2001 May; 49(5):590-6. PubMed ID: 11357949 [TBL] [Abstract][Full Text] [Related]
20. Identification and sizing of GAA trinucleotide repeat expansion, investigation for D-loop variations and mitochondrial deletions in Iranian patients with Friedreich's ataxia. Houshmand M; Panahi MS; Nafisi S; Soltanzadeh A; Alkandari FM Mitochondrion; 2006 Apr; 6(2):82-8. PubMed ID: 16581313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]